The FDA has granted priority review to ifinatamab deruxtecan, also known as I-DXd, for use in adult patients with previously treated extensive-stage small cell lung cancer. The treatment is intended for patients who have experienced disease progression on or after platinum-based chemotherapy. There is also mention of a breakthrough therapy designation for ifinatamab deruxtecan in this context, although it is unclear if this is a separate or related development.